Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Pantelis A. Sarafidis, Maria Eleni Alexandrou & Luis M. Ruilope. (2017) A review of chemical therapies for treating diabetic hypertension. Expert Opinion on Pharmacotherapy 18:9, pages 909-923.
Read now
Read now
. (2007) 2007 ESH‐ESC Guidelines for the management of arterial hypertension. Blood Pressure 16:3, pages 135-232.
Read now
Read now
Peter M. Nilsson, Bo Hedblad, Jill Donaldson & Göran Berglund. (2007) Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1‐year treatment in non‐diabetic subjects with insulin resistance. Blood Pressure 16:2, pages 95-100.
Read now
Read now
Articles from other publishers (48)
Peter M. Nilsson & Andrea Natali. 2023. Blood Pressure Disorders in Diabetes Mellitus. Blood Pressure Disorders in Diabetes Mellitus
119
128
.
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2020. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
131
159
.
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2019. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
1
29
.
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2019. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
1
29
.
Jing-Bo Jiang, James A. Balschi, Francis X. McGowan Jr & Huamei He. 2018. Cardiotoxicity. Cardiotoxicity.
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2018. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
131
159
.
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
29
.
Cecilia Chi, Jennifer Snaith & Jenny E. Gunton. (2017) Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes. Heart, Lung and Circulation 26:11, pages 1133-1141.
Crossref
Crossref
Po-Jen Hsiao, Kun-Lin Wu, Szu-Han Chiu, Jenq-Shyong Chan, Yuh-Feng Lin, Chung-Ze Wu, Chia-Chao Wu, SenYeong Kao, Te-Chao Fang, Shih-Hua Lin & Jin-Shuen Chen. (2016) Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan. Clinical and Experimental Nephrology 21:4, pages 694-704.
Crossref
Crossref
Peter M. Nilsson. 2017. Textbook of Diabetes. Textbook of Diabetes
629
642
.
Andrew J. Krentz. (2016) Hypertension in type 2 diabetes: impact of glucose-lowering medications. Cardiovascular Endocrinology 5:4, pages 137-143.
Crossref
Crossref
R. A. DeFronzo, R. Chilton, L. Norton, G. Clarke, R. E. J. Ryder & M. Abdul‐Ghani. (2016) Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor. Diabetes, Obesity and Metabolism 18:5, pages 454-462.
Crossref
Crossref
Ele Ferrannini & Ralph A. DeFronzo. (2015) Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal 36:34, pages 2288-2296.
Crossref
Crossref
Lin-Fang Lan, Lu Zheng, Xian Yang, Xiao-Tan Ji, Yu-Hua Fan & Jin-Sheng Zeng. (2015) Peroxisome Proliferator-activated Receptor-? Agonist Pioglitazone Ameliorates White Matter Lesion and Cognitive Impairment in Hypertensive Rats. CNS Neuroscience & Therapeutics 21:5, pages 410-416.
Crossref
Crossref
Jacob D. Peuler & Laura E. Phelps. (2015) Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents. Journal of Smooth Muscle Research 51:0, pages 22-36.
Crossref
Crossref
Pantelis A. Sarafidis, Panagiotis I. Georgianos, Pantelis E. Zebekakis & Athanasios J. Manolis. 2015. ACEi and ARBS in Hypertension and Heart Failure. ACEi and ARBS in Hypertension and Heart Failure
73
118
.
Xiang Kong, Ming-zhe Ma, Li Qin, Yan Zhang, Xiao-yong Li, Guo-dong Wang, Qing Su & Dao-you Zhang. (2013) Pioglitazone enhances the blood pressure-lowering effect of losartan via synergistic attenuation of angiotensin II-induced vasoconstriction. Journal of the Renin-Angiotensin-Aldosterone System 15:3, pages 259-270.
Crossref
Crossref
Julio Rosenstock, Marisa Vico, Li Wei, Afshin Salsali & James F. List. (2012) Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy. Diabetes Care 35:7, pages 1473-1478.
Crossref
Crossref
Raquel Hernanz, ?ngela Mart?n, Jose V P?rez-Gir?n, Roberto Palacios, Ana M Briones, Marta Miguel, Mercedes Salaices & Mar?a J Alonso. (2012) Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function. British Journal of Pharmacology 166:4, pages 1303-1319.
Crossref
Crossref
I. Lazich, P. Sarafidis, E. de Guzman, A. Patel, R. Oliva & G. Bakris. (2011) Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes, Obesity and Metabolism 14:2, pages 181-186.
Crossref
Crossref
Pantelis A. Sarafidis, Panagiotis I. Georgianos & Anastasios N. Lasaridis. (2011) PPAR-γ Agonism for Cardiovascular and Renal Protection. Cardiovascular Therapeutics 29:6, pages 377-384.
Crossref
Crossref
Soo Lim, Jean-Pierre Despres & Kwang Kon Koh. (2011) Prevention of Atherosclerosis in Overweight/Obese Patients. Circulation Journal 75:5, pages 1019-1027.
Crossref
Crossref
Vivian A. Fonseca. (2011) Incretin-Based Therapies in Complex Patients: Practical Implications and Opportunities for Maximizing Clinical Outcomes: A Discussion with Dr. Vivian A. Fonseca. The American Journal of Medicine 124:1, pages S54-S61.
Crossref
Crossref
Peter M. Nilsson & Renata Cifkova. (2010) Blood Pressure-Lowering Aspects of Lipid-Lowering and Anti-Diabetic Drugs. Pharmaceuticals 4:1, pages 1-6.
Crossref
Crossref
G. Schernthaner & R. J. Chilton. (2010) Cardiovascular risk and thiazolidinediones—what do meta‐analyses really tell us?. Diabetes, Obesity and Metabolism 12:12, pages 1023-1035.
Crossref
Crossref
A. Zanchi, M. Maillard, F. R. Jornayvaz, M. Vinciguerra, P. Deleaval, J. Nussberger, M. Burnier & A. Pechere-Bertschi. (2010) Effects of the peroxisome proliferator-activated receptor (PPAR)-γ agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. Diabetologia 53:8, pages 1568-1575.
Crossref
Crossref
E. Erdmann & R. Wilcox. (2009) Pioglitazone and mechanisms of CV protection. QJM 103:4, pages 213-228.
Crossref
Crossref
Kwang Kon Koh, Seung Hwan Han, Pyung Chun Oh, Eak Kyun Shin & Michael J. Quon. (2010) Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid-RAAS interaction. Atherosclerosis 209:2, pages 307-313.
Crossref
Crossref
Laura E. Phelps & Jacob D. Peuler. (2010) Evidence of direct smooth muscle relaxant effects of the fibrate gemfibrozil. Journal of Smooth Muscle Research 46:3, pages 125-142.
Crossref
Crossref
Rigas Kalaitzidis & George Bakris. (2009) Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes, Obesity and Metabolism 11:8, pages 757-769.
Crossref
Crossref
Elizabeth W Blake & Julie M Sease. (2009) Effect of Diabetes Medications on Cardiovascular Risk and Surrogate Markers in Patients with Type 2 Diabetes. Journal of Pharmacy Technology 25:1, pages 24-36.
Crossref
Crossref
Zhenchan Lu, Birong Dong, Xianming Mo, Tie Chen, Hongmei Wu, Yanling Zhang & Hengyi Xiao. (2008) Pro12Ala polymorphism in PPAR ? 2 associated with essential hypertension in Chinese nonagenarians/centenarians. Experimental Gerontology 43:12, pages 1108-1113.
Crossref
Crossref
Amelia Brunani, Antonio Liuzzi, AnnaMaria Titon, Salvatore Graci, Giovanna Castagna, Gian Carlo Viberti & Luca A. Gondoni. (2008) Evaluation of Rosiglitazone Administration on Cardiovascular Function in Severe Obesity. Clinical Cardiology 31:12, pages 602-606.
Crossref
Crossref
Luis Ruilope & Julian Segura. 2008. Manual of Hypertension of The European Society of Hypertension. Manual of Hypertension of The European Society of Hypertension
199
205
.
Pantelis A. Sarafidis. (2008) Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. Fundamental & Clinical Pharmacology 22:3, pages 247-264.
Crossref
Crossref
Peter M Nilsson. (2008) Thiazolidinediones for elderly patients with Type 2 diabetes: safe or not?. Aging Health 4:2, pages 131-135.
Crossref
Crossref
Philip Raskin. (2008) Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. Diabetes/Metabolism Research and Reviews 24:1, pages 3-13.
Crossref
Crossref
Gy?rgy Jermendy. (2007) PPAR? agonists?Antidiabetic drugs with a potential role in the treatment of diseases other than diabetes. Diabetes Research and Clinical Practice 78:3, pages S29-S39.
Crossref
Crossref
. (2007) Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007. Revista Española de Cardiología 60:9, pages 968.e1-968.e94.
Crossref
Crossref
Panagiotis C. Stafylas, Pantelis A. Sarafidis & Anastasios N. Lasaridis. (2007) Rosiglitazone and Cardiovascular Risk: Weighing Recent Evidence. Journal of the CardioMetabolic Syndrome 2:4, pages 295-296.
Crossref
Crossref
Thomas D. Giles & Gary E. Sander. (2007) Effects of thiazolidinediones on blood pressure. Current Hypertension Reports 9:4, pages 332-337.
Crossref
Crossref
Pantelis A. Sarafidis, Samy I. McFarlane & George L. Bakris. (2007) Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Current Diabetes Reports 7:3, pages 191-199.
Crossref
Crossref
Lee-Sun New, Sudipta Saha, Michie M. K. Ong, Urs Alex Boelsterli & Eric C. Y. Chan. (2007) Pharmacokinetic study of intraperitoneally administered troglitazone in mice using ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 21:6, pages 982-988.
Crossref
Crossref
Jose A Garcia-Donaire, Julian Segura & Luis M Ruilope. (2007) Clinical trials in nephrology: success or failure. Current Opinion in Nephrology and Hypertension 16:2, pages 59-63.
Crossref
Crossref
Pantelis A. Sarafidis & George L. Bakris. (2007) Insulin and Endothelin: An Interplay Contributing to Hypertension Development?. The Journal of Clinical Endocrinology & Metabolism 92:2, pages 379-385.
Crossref
Crossref
Toshiaki Takahashi, Hidehiko Ono, Yuko Ono, Toshihiko Ishimitsu & Hiroaki Matsuoka. (2007) Combination Therapy With Telmisartan and Spironolactone Alleviates L-NAME Exacerbated Nephrosclerosis With an Increase in PPAR-γ and Decrease in TGF-β1. International Heart Journal 48:5, pages 637-647.
Crossref
Crossref
John M. Flack, Samar A. Nasser, Mark Britton, Anna B. Valina-Toth, Vineeta Ahooja & Shannon M. O'Connor. 2007. Comprehensive Hypertension. Comprehensive Hypertension
707
718
.
Gang Wang. (2006) Effects of impaired glucose metabolism on heart rate variability and blood pessure variability in essential hpertensive patients. Journal of Huazhong University of Science and Technology 26:6, pages 654-656.
Crossref
Crossref